First in Human Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1214784

NCT02212080 ↗

Phase 1 Completed 48 enrolled Bayer

RandomizedParallel-groupQuadruple-blindBasic science

Summary

This study is a first in human study that will investigate the safety, tolerability and pharmacokinetics of ascending single doses of BAY1214784 using a placebo controlled, randomized, single center design. In addition the bioavailability of two different liquid formulations will be compared.

Timeline

Start: 2014-09
Primary completion: 2015-03
Completion: 2015-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BAY-784	Unknown	5 mg	Oral
Subject	BAY-784	Unknown	20 mg	Oral
Subject	BAY-784	Unknown	60 mg	Oral
Subject	BAY-784	Unknown	150 mg	Oral
Subject	BAY-784	Unknown	300 mg	Oral
Subject	BAY-784	Unknown	600 mg	Oral
Subject	BAY-784	Unknown	1000 mg	Oral

Indications

No indication recorded.